Gap's Give and Get Program is Back, Starting July 30
For four days, from July 30 through August 2, clothier the Gap will be bringing back the Give and Get Program that benefits the Leukemia & Lymphoma Society while saving you a few bucks on clothes.
All you need to do is print a barcode (available here) and bring it to the counter at any Gap, Gap Outlet, Banana Republic, Banana Republic Factory Stores or Old Navy store along with your planned purchases. You'll receive 30% off those purchases—a very good deal, hard to deny that—and the store will donate 5% of the amount you spend to the Leukemia & Lymphoma Society.
The bar code is reusable in-store (not on-line) as often as you can reuse it during the four day event.
The Gap's spring Give and Get program raised $600,000 for research. Let's hope the summer program does just as well.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
